morphism was overrepresented in hypercalciuric stone formers. Urinary calcium excretion was not associated with CaSR polymorphism in the present sample.
Introduction
Idiopathic hypercalciuria is one of the most common metabolic disturbances found in nephrolithiasis patients, occurring in up to 50% of cases but in less than 10% of the general population [1] [2] [3] . Idiopathic hypercalciuria represents a systemic abnormality of calcium homeostasis in which a dysregulation of calcium transport takes place in the kidneys, intestine and bones [4, 5] . Pathophysiological mechanisms may involve a primary renal calcium leak, primary intestinal calcium hyperabsorption, or an imbalance between bone resorption and formation [6] . Such disturbances can occur simultaneously, and secondary compensatory changes involve multiple hormones such as parathyroid hormone (PTH) and 1,25-dihydroxy-vitamin D 3 [1, 25(OH) 2 D 3 ] [7] . Serum 1,25(OH) 2 D 3 levels in patients with idiopathic hypercalciuria form a continuum from normal to high [8] , so that elevated circulating 1,25(OH) 2 D 3 levels may account for the hypercalciuria in some but not all of these patients. Favus et al. [8] observed that the number of peripheral blood monocytes of vitamin D receptors (VDRs) Ferreira /Pereira /Pfeferman Heilberg Nephron Clin Pract 2010;114:c135-c144 c136 was twice as high in patients with idiopathic hypercalciuria compared to controls although the mean serum calcitriol levels were not. Therefore, a possible mechanism that could explain increased absorption of calcium in the gut, as well as bone mineral lability and abnormal renal tubule conservation of calcium would be altered tissue vitamin D response. Experimental studies have shown that the intestine, bones and kidneys of genetic hypercalciuric stone-forming rats exhibited increased numbers of vitamin D receptors [5, 9] and that prolongation of VDR half-life increases VDR tissue levels mediating increased VDR-regulated genes [9] . Finally, a link between idiopathic calcium stone formation and the microsatellite marker D12S339 (near the VDR locus) has been established in humans [10] .
Almost half of the patients with idiopathic hypercalciuria have a positive family history of kidney stones [7, 11] and data from different geographic areas suggest a genetic background for hypercalciuria explaining at least 50% of its variance [11] . Nevertheless, idiopathic hypercalciuria is a complex trait that does not fit into classical Mendelian categories.
Several studies about common allelic variations in VDR in disorders of calcium metabolism, using Bsm I, Apa I, Taq I and Fok I restriction enzymes have been performed, but the results were controversial . While some studies disclosed an association between VDR polymorphism and bone mineral density (BMD) [12] [13] [14] [15] , others did not [16] [17] [18] [19] . Although the link between stone formation and VDR has not yet been clarified, and these polymorphisms do not alter the amino acid sequence of the VDR protein, allelic differences in the 3 untranslated region may alter the regulation of messenger RNA stability and/or translation and thus affect vitamin D activity, or even mediate calcitriol action in the regulation of expression of other target genes involved in renal tubular calcium reabsorption [12, 27, 33] . In addition, even if a specific VDR genotype does not provide evidence for a VDR defect per se, it could be a marker for the disease that could aid in the identification of a possible disease locus [12] . Evaluation of VDR polymorphisms among kidney stone formers, hypercalciuric or not, have shown distinct findings [16, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] . Some investigators found a positive association between polymorphic variations in VDR gene with risk or recurrence of stone formation [27] [28] [29] but other studies were negative [30, 31] . As for urinary calcium, a few studies reported higher calcium excretion related to specific genotypes [21, 24, 32] while others did not [20, 22, 25, 26] .
The G-protein-coupled extracellular-calcium-sensing receptor (CaSR) is a key regulator of PTH secretion and renal tubular calcium reabsorption in response to blood calcium levels [34] . Activation of the renal CaSR may decrease renal tubule calcium reabsorption and cause hypercalciuria through suppression of calciumsensitive potassium channel activity. The CaSR gene is also regulated by VDR, and pathologically elevated VDR levels observed in genetic hypercalciuric stone-forming rats have been implicated in the increased renal CaSR mRNA induced by 1,25(OH) 2 D 3 , possibly contributing to hypercalciuria [35] . Three single-nucleotide polymorphisms, causing nonconservative amino acid changes have been described on exon 7, encoding the intracellular domain of CaSR. The most common single-nucleotide polymorphism is represented by a substitution of guanine/thymine at codon 986, leading to the Ala986Ser variant [36, 37] and the other two, less frequent substitutions, are Arg990Gly and Gln1011Glu (substitutions of adenine/guanine at codon 990 and cytosine/guanine at codon 1011, respectively) [37] . One of the pioneering studies performed by Cole et al. [36] showed a positive association between serum calcium and A986S polymorphism in women. Subsequent association studies between different CaSR polymorphisms and urinary calcium have been controversial, resulting in positive [38] [39] [40] [41] [42] or negative findings [43, 44] . Nevertheless, only a few of these studies had been conducted in calcium-stoneforming patients [38, 42] . Association with BMD was detected by some investigators [45, 46] but not by others [43, [47] [48] [49] .
Therefore, the aim of the present study was to evaluate a potential association of VDR and CaSR gene polymorphisms with urinary calcium excretion in stone-forming patients.
Subjects and Methods
Two-hundred and one adult calcium-stone-forming patients (103 males and 98 females) from the Renal Lithiasis Unit of the Nephrology Division of the Federal University of São Paulo were included in the present study. Stone disease had been diagnosed on the basis of renal colic with confirmed hematuria and voiding of a calculus and/or previous surgical or endoscopic removal of stone(s), and/or radiographic evidence of stone(s). Patients were classified as normocalciuric or hypercalciuric based on the results of 24-hour urine samples available from their medical records. Data concerning the presence of other metabolic abnormalities related to stone formation were also obtained from these records. As the report of stone analysis was not available in most of the records, only those patients with evidence of uni-or bilateral ra-c137 dio-opaque stones, consistent with calcium composition, were selected for this study. Exclusion criteria included: abnormal renal function, pregnant or postmenopausal women, men aged 6 65 years, cystinuria, renal tubular acidosis, inflammatory bowel disease, primary hyperparathyroidism and other diseases affecting calcium metabolism (hyperthyroidism, acromegaly, sarcoidosis, diabetes or neoplasia), use of drugs such as corticosteroids, anticonvulsants, estrogen or vitamin D. Written consent was obtained from all patients and the study was approved by the Ethics Committee of the Federal University of São Paulo.
All patients had been previously submitted to a metabolic evaluation including serum determinations of calcium, creatinine, uric acid and 24-hour urine collections (mean of 2 nonconsecutive samples), under an unrestricted diet. Idiopathic hypercalciuria was defined by serum calcium within normal limits and 24-hour urinary excretion of calcium 6 250 or 300 mg/24 h (for females and males, respectively). Hyperuricosuria was considered as urinary uric acid 1 750 or 800 mg/24 h (for females and males, respectively), hypocitraturia as urinary citrate ! 320 mg/ 24 h. Calcium was determined by atomic absorption spectrophotometry (Perkin Elmer Atomic Spectrophotometer 3110; Norwalk, Conn., USA), uric acid, by the uricase method (Hitachi 912; Roche, Mannheim, Germany) and citrate by an enzymatic assay using citrate lyase as described elsewhere [50] . Creatinine was determined according to a modified Jaffé reaction by isotope dilution mass spectrometry. Sodium was determined by an ion-selective electrode. BMD was assessed by dual-energy X-ray absorptiometry at lumbar spine and femoral neck sites, using a DPX model apparatus (Lunar Radiation Corporation, Madison, Wisc., USA). Data concerning evaluation of BMD were available from 146 medical records. Osteopenia was defined by a T-score value below -1.0 in the L 2 -L 4 lumbar spine and/or femur neck according to WHO criteria [51] .
VDR and CaSR Genotyping
Blood samples were obtained for genotyping of both VDR and CaSR polymorphisms and genomic DNA was extracted from peripheral blood leukocytes using the Puregene DNA Isolation Kit (Gentra Systems, Minneapolis, Minn., USA).
VDR gene polymorphism was identified for polymerase chain reaction (PCR) amplification of the Bsm I restriction site located between exon 7 and the 3 -UTR, using the following primers [12] : 5 -CAACCAAGACTACAAGTACCG-CGTCAGTGA-3 and 5 -AACCAGCGGGAAGAGGTCAAGGG-3 . Briefly, PCR was carried out in a 50-l reaction volume containing 500 ng of DNA, 0.4 M of each primer, 0.5 nmol dNTPs, 1.5 m M MgCl 2 and 2.5 U of Taq DNA polymerase (all reagents from Invitrogen). The PCR conditions were 94 ° C, 5 min, 94 ° C, 1 min, 61 ° C, 90 s, 72 ° C, 2 min, for 30 cycles and then 72 ° C for 10 min and 4 ° C, using an MJ Research thermal cycler. PCR products were submitted to digestion with the Bsm I endonuclease at 65 ° C for 3 h, and then separated electrophoretically on 2% agarose gel containing ethidium bromide. BsmI alleles were defined by capitals in the absence of the restriction site (B), and lowercase letters in the presence of the restriction site (b).
Part of exon 7 of the CaSR gene comprising the 3 single-nucleotide polymorphisms (G/T at codon 986, A/G at codon 990, and C/G at codon 1011) were amplified by PCR as described elsewhere [38] using primers 5 -CAGAAGGTCATCTTTGGCAGCGGCA-3 and 5 -TGCAGACCTGTTTCCTGGACGGTC-3 , sequences that flank the polymorphic site giving an amplimer of 206 bp. Purified PCR products were submitted to direct sequencing using a ready reaction mix (ABI PRISM Big-Dye Terminator Cycle Sequencing Ready Reaction Kit; Applied Biosystems, Foster City, Calif., USA) and the same forward primer as for PCR. Sequence products were generated during 25 cycles of the following steps: 15 s at 96 ° C, 10 s at 50 ° C, and 2 min at 60 ° C. Nonincorporated dye terminators were removed by ethanol/sodium acetate precipitation. Afterwards, dyed samples were denatured in 20 l of Template Suppression Reagent (Applied Biosystems) at 95 ° C for 10 min and cooled on ice for 15 min. The ABI PRISM 310 Genetic Analyzer (Applied Biosystems) was used for capillary electrophoresis.
Statistical Analysis
Data are presented as means 8 standard deviation (SD). The Mann-Withney test was used to compare normocalciuric versus hypercalciuric patients. The Kruskal-Wallis analysis of variance test was performed to compare differences between the different genotypes or haplotypes of each polymorphism in the normocalciuric or hypercalciuric groups of patients. The 2 or Fisher's exact test was used to compare the frequencies of VDR genotypes and CaSR haplotypes in the normocalciuric and hypercalciuric groups. Relative risk to be hypercalciuric was estimated by calculation of the odds ratio (OR) and its 95% confidence interval (95% CI). Linkage disequilibrium between SNPs and allele and haplotype frequencies were calculated using Haploview 3.32 software. Statistical power calculations were conducted with Quanto version 1.2.3 software using empirically observed allele frequencies and the hypercalciuric phenotype. For the studied polymorphism of the VDR gene, our sample had 80% power to disclose an OR of at least 2.2 associated with the b allele. For the much rarer CaSR studied polymorphisms, our sample allowed 80% power to detect OR in the order of 3.0, 3.3 and 3.7, respectively, for the 986S, 990G, and 1011E variant alleles. 
Results
The allele frequencies of the VDR polymorphism in the whole sample of 201 calcium-stone-forming patients were 16, 49 and 35%, respectively for BB , Bb and bb , as shown in table 1 . These genotype frequencies at polymorphic sites did not deviate from those expected according to the Hardy-Weinberg equilibrium. Analysis of patients grouped by these 3 genotypes showed no differences in mean age or gender distribution. In bb patients, mean urinary excretion of calcium was higher than in Bb patients (270 8 102 vs. 228 8 102 mg/24 h), but the difference did not reach statistical significance. The other mean serum and urine biochemical parameters were not statistically different between VDR genotypes.
Patients were then classified as hypercalciuric (n = 100, 52 M/48 F, 38 8 11 years old) or normocalciuric (n = 101, 51 M/50 F, 39 8 11 years old). Hypercalciuric patients also exhibited 43% of hypocitraturia and 17% of hyperuricosuria while hypocitraturia and hyperuricosuria were present in 34 and 3% of normocalciuric patients, respectively. These disturbances appeared individually or in association (data not shown in tables). As shown in figure 1 , the bb genotype was overrepresented in the hypercalciuric group compared to the normocalciuric group (43 vs. 27%, p ! 0.05). The distribution of VDR genotypes in osteopenic or normal BMD patients was not statistically different, as illustrated in figure 2 . Table 2 shows serum and urinary parameters in these subgroups of normo-and hypercalciuric patients grouped by VDR genotypes. Gender distribution, mean age, weight and serum parameters were not statistically different between the normo-and hypercalciuric groups with the same genotype or among genotypes, but the number of hypercalciuric patients presenting with the bb genotype was significantly higher. Bb and bb hypercalciuric patients presented significantly higher mean urinary uric acid excretion versus normocalciurics with the same genotype. Lower urinary citrate excretion was observed in bb when compared with Bb or BB hypercalciuric patients, without reaching statistical significance. When we examined the VDR alleles in normo-and hypercalciuric patients regarding recurrence, as seen in table 3 , we did not observe any statistically significant differences in genotype distribution in patients who exhibited or not new stone formation.
With respect to CaSR polymorphisms in the whole sample, the 986S, 990G, and 1011E variant alleles were detected in 5, 4 and 3% of the patients, respectively. Homozygote genotypes for these variants were not found and the allele distribution conformed to the Hardy-Weinberg equilibrium for each CaSR polymorphism. No linkage disequilibrium was observed among the 3 single nucleotide polymorphisms (data not shown). Five CaSR haplotypes were identified in the present series, named according to the amino acid coded at the 3 studied polymorphic sites. Their frequencies were: 94% ARQ (wild type), 3% figure 3 , the frequencies of each haplotype were not significantly different between the normo-and hypercalciuric groups.
Discussion
There is strong evidence that heredity is an important contributor to the prevalence of nephrolithiasis [7, 11, 52, 53] . The hypercalciuric phenotype has been implicated in the familial aggregation of stone formation [54] ; kindreds with hypercalciuria have been well characterized [55, 56] , and family-based studies showed a heritability for urinary calcium excretion to be more than 50% [57, 58] . The direct effects of 1,25(OH) 2 D 3 on renal calcium reabsorption are complex and not well understood because of interactions with parathyroid hormone and simultaneous effects on intestine and bone. Hyperresponsiveness of genetic hypercalciuric stone-forming rats to 1,25(OH) 2 D 3 is unique and affects the VDR-responsive gene in 1,25(OH) 2 D 3 target tissues possibly contributing to hypercalciuria and stone formation [33] . Given the potential susceptibility locus in the vicinity of the VDR gene [10] for idiopathic stone formation and the influence of calcium-sensing receptor in calcium excretion [34] , both VDR and CaSR genes have been considered as candidate genes for idiopathic hypercalciuria. In the present study, we aimed at evaluating the association of both VDR and CaSR polymorphisms with urinary calcium excretion in calcium-stone-forming patients.
We found a higher prevalence of the bb genotype among hypercalciuric compared to normocalciuric patients. Inasmuch as bb genotype has been classically related to a better BMD [12] [13] [14] [15] , its prevalence was expected to be lower among hypercalciuric patients, who traditionally exhibit higher rates of low BMD [59] [60] [61] . Anyway, our findings regarding overrepresentation of the bb genotype agree well with the reports of Rendina et al. [24] and Relan et al. [32] , who also observed that the presence of two copies of the b allele was more common in hypercalciuric patients. Interestingly, although a higher prevalence of both ( ApaI ) aa and ( BsmI ) bb genotypes in fasting hypercalciuric subjects disclosed in the former study [24] , such bb patients also presented a significantly lower instead of a higher mean BMD. In the present series, VDR allele distribution did not differ between osteopenic or normal BMD patients. In a previous evaluation by our group [16] , conducted exclusively in hypercalciuric calcium-stone-forming patients, we also found that VDR polymorphism was not associated with loss of BMD. Nor did Vezzoli et al. [22] find an association of FokI polymorphism with BMD in hypercalciuric patients. On the other hand, although several studies in the past have suggested that multiple VDR polymorphisms (including BsmI ) influence the regulation of BMD [12] [13] [14] [15] , a more recent multicenter prospective trial [17] involving around 26,000 participants, as well as other studies [18, 19] , have not confirmed such an association. Two additional studies reported an association between bb genotype with low rather than higher BMD [20, 62] .
Such observations of an association of VDR polymorphisms with calcium excretion but not with BMD are intriguing. According to Dawson-Hughes et al. [63] BB homozygous postmenopausal women, when exposed to low calcium intake, present less efficient intestinal calcium absorption than bb women, despite similar levels of 1,25(OH) 2 D 3 , pointing to VDR as functionally different between BB and bb alleles. In agreement with our findings, these investigators also observed that the bb group exhibited somewhat higher levels (albeit not significant) of calcium excretion than BB , coupled with similar BMD, irrespective of dietary calcium intake. Although the altered gut VDR status in bb variants might have been responsible for a better ability to increase fractional calcium absorption [63] , the patients exhibited not only slightly higher levels of urinary calcium but also somewhat lower serum PTH. The increase in calcium excretion in bb genotypes may thus be ascribed to PTH suppression induced by increased activity of vitamin D. It is noteworthy that most studies which found a positive association of bb alleles with BMD, had been performed in non-calcium-stone-forming women [12] [13] [14] [15] whereas no association was found in healthy males [19] . Since males and females were equally distributed in the present study, the samples are not comparable. We also observed that the bb homozygous patients exhibited a slightly higher mean urinary calcium excretion (although not significant) than heterozygous Bb , in accordance with other investigators who reported the same results in stone formers [21, 32] or non-stone formers [64] . We believe that the small differences in mean urinary calcium excretion per genotype group might not have reached statistical significance because of the limited sample size presently analyzed. In hypercalciuric lithiasic children, Seyhan et al. [29] found c141 a higher frequency of tt genotypes. Conversely, other studies did not find any association between calcium excretion in nephrolithiasis patients with either BsmI polymorphism [20, 26, 65] or other polymorphisms as TaqI , ApaI or FokI [22, [26] [27] [28] [29] [30] 66] . In some reports in which hypercalciuria had been ascribed to intestinal calcium hyperabsorption or renal leak, no association between BsmI polymorphism with absorptive hypercalciuria was found [20, 25] while overrepresentation of bb was observed among those exhibiting renal leak [24] . Since we found no differences of VDR alleles between absorptive or fasting hypercalciuric patients in a prior study encompassing a smaller number of patients [16] , data regarding urinary calcium were pooled in the present analysis for comparison between normo-and hypercalciuric patients.
In our sample, hypercalciuric patients with one or two copies of the b allele also presented a statistically higher mean urinary uric acid excretion compared to normocalciuric subgroups and a nonsignificant trend for lower urinary citrate excretion when compared to hypercalciuric BB patients. In another study in stone formers, bb and TT genotypes were found to be associated with the presence of hypocitraturia [23] . However, the reasons why VDR polymorphisms might have affected the urinary excretion of uric acid or citrate remain unclear. Finally, we did not find any association between BsmI alleles and stone recurrence in the normocalciuric or hypercalciuric groups. None of the studies that focused on the association of VDR polymorphism with recurrence of stone disease had employed Bsm I endonuclease. With regard to other polymorphisms, some authors have an association with recurrence or severity of stone disease with either the t allele [27, 29] or the FF genotype [28] , while still other investigators observed nonsignificant trends for the TT genotype [30] .
Taken together, conflicting results in the literature may be due, at least in part, to small sample sizes, differences in the studied populations (pre-and postmenopausal women or kidney stone formers), sex, age, and exact VDR polymorphism that had been investigated.
With respect to CaSR polymorphisms, association with serum calcium have been reported in some studies [12, 36, 67, 68] but not in all of them [39, 47, 48, 69] . Few studies focused on the association of CaSR with urinary calcium in calcium-stone-forming patients [38, 42] . In the present study, the frequencies of all 3 CaSR polymorphisms in the whole sample were very low (up to 5%). Although the presence of any variant allele conferred a 2.8-fold increased risk of presenting hypercalciuria, we did not find any statistical differences among the various haplotype distributions in normocalciuric versus hypercalciuric patients. These findings are in contrast with the data of Vezzoli et al. [38] who observed that R990G polymorphism was associated with increased urinary calcium in calcium-stone-forming patients. A subsequent functional study performed by the same group [40] with transfected cells containing the 990G variant showed a gain-of-function of the CaSR. A 5.5-fold increased risk for the G allele to develop hypercalciuria was disclosed, but the study had not been performed in stone formers, but in osteoporotic women instead [40] . It is also possible to infer that in such a setting, hypercalciuria was consequent to increased bone resorption [70] rather than being a primary mechanism leading to loss of bone mass. On the other hand, in another functional study, Harding et al. [43] did not find any change in CaSR activity in cells transfected for the 990G allele. These investigators also reported a lack of association between R990G or other CaSR polymorphisms with urinary calcium in twin pairs [43] . In another Italian cohort, Scillitani et al. [41] reported an overrepresentation of the AGQ haplotype in stone-forming patients with primary hyperparathyroidism. Although an association with calcium clearance was disclosed in that study, the urinary calcium values had been obtained from urine spot samples rather than from 24-hour urine samples, which represent the gold-standard method. One limitation of this and other studies involving the R990G polymorphism and the Q1011E is the relative rarity of the 990G variant. We have currently found no homozygous patients for any of the 3 polymorphisms. Nevertheless, except for recent data by Cole et al. [36] , who found 2.9% of stone formers to be homozygous for 990G polymorphism, another study reported 1 single case in the control group or rates up to 1.6% of homozygous G among hypercalciuric patients [40] , so that the results have mostly considered the heterozygous patients for statistical purposes.
Although the present sample is not large and the statistic power of the present analysis is thus not optimal, some important points must be raised. First, genotype frequencies of either VDR or CaSR polymorphic sites did not deviate from the expected Hardy-Weinberg equilibrium in the current series. In addition, previous positive studies focusing on the association between calcium excretion and BsmI VDR polymorphisms among adult stone formers have involved around 150 patients [24, 32] , an only moderately higher number than ours, while the negative studies included a much lower number of pa-tients, less than 40 [20, 21] . As for the CaSR association studies with 24-hour calcium excretion in lithiasic patients [38] , the size of the sample was similar to ours. In most of the studies aimed to address associations of polymorphisms with urinary calcium excretion, some of the difficulties on achieving a higher number of patients rely on the requirement for timed urine collection over 24 h, which is laborious and prone to collection failure, albeit necessary for a more adequate definition of the hypercalciuric phenotype.
In conclusion, the present study showed an association between urinary calcium excretion and bb genotype of VDR polymorphism, but not with CaSR polymorphisms. The described associations need to be replicated in larger samples and, ideally, should involve the use of a continuous variable (urinary calcium excretion) sampled in individuals representative of the general population.
